Search Results - "Maharry, K"

Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia by Dorrance, A M, Neviani, P, Ferenchak, G J, Huang, X, Nicolet, D, Maharry, K S, Ozer, H G, Hoellarbauer, P, Khalife, J, Hill, E B, Yadav, M, Bolon, B N, Lee, R J, Lee, L J, Croce, C M, Garzon, R, Caligiuri, M A, Bloomfield, C D, Marcucci, G

“…Current treatments for acute myeloid leukemia (AML) are designed to target rapidly dividing blast populations with limited success in eradicating the…”
Get full text

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia by Niederwieser, C, Kohlschmidt, J, Volinia, S, Whitman, S P, Metzeler, K H, Eisfeld, A-K, Maharry, K, Yan, P, Frankhouser, D, Becker, H, Schwind, S, Carroll, A J, Nicolet, D, Mendler, J H, Curfman, J P, Wu, Y-Z, Baer, M R, Powell, B L, Kolitz, J E, Moore, J O, Carter, T H, Bundschuh, R, Larson, R A, Stone, R M, Mrózek, K, Marcucci, G, Bloomfield, C D

“…DNMT3B encodes a DNA methyltransferase implicated in aberrant epigenetic changes contributing to leukemogenesis. We tested whether DNMT3B expression, measured…”
Get full text

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer by Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Gollerkeri, A., Maharry, K., Loupakis, F., Hong, Y., Steeghs, N., Guren, T., Arkenau, H., García Alfonso, P., Sandor, V., Christy-Bittel, J., Anderson, L., Tabernero, J.

Get full text

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer by Van Cutsem, E., Cuyle, P., Huijberts, S., Schellens, J., Elez, E., Yaeger, R., Fakih, M., Montagut, C., Peeters, M., Desai, J., Yoshino, T., Ciardiello, F., Wasan, H., Maharry, K., Christy-Bittel, J., Gollerkeri, A., Kopetz, S., Grothey, A., Tabernero, J.

Get full text

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study by Tabernero, J., Velez, L., Trevino, T.L., Grothey, A., Yaeger, R., Van Cutsem, E., Wasan, H., Desai, J., Ciardiello, F., Yoshino, T., Gollerkeri, A., Maharry, K., Christy-Bittel, J., Kopetz, S.

“…Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer…”
Get full text

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy by Whitman, S P, Kohlschmidt, J, Maharry, K, Volinia, S, Mrózek, K, Nicolet, D, Schwind, S, Becker, H, Metzeler, K H, Mendler, J H, Eisfeld, A-K, Carroll, A J, Powell, B L, Carter, T H, Baer, M R, Kolitz, J E, Park, I-K, Stone, R M, Caligiuri, M A, Marcucci, G, Bloomfield, C D

“…Emerging data demonstrate important roles for the TYRO3/AXL/MERTK receptor tyrosine kinase (TAM RTK) family in diverse cancers. We investigated the prognostic…”
Get full text

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia by Metzeler, K H, Maharry, K, Kohlschmidt, J, Volinia, S, Mrózek, K, Becker, H, Nicolet, D, Whitman, S P, Mendler, J H, Schwind, S, Eisfeld, A-K, Wu, Y-Z, Powell, B L, Carter, T H, Wetzler, M, Kolitz, J E, Baer, M R, Carroll, A J, Stone, R M, Caligiuri, M A, Marcucci, G, Bloomfield, C D

“…Acute myeloid leukemia (AML) is hypothesized to be sustained by self-renewing leukemia stem cells (LSCs). Recently, gene expression signatures (GES) from…”
Get full text

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 by Becker, H, Maharry, K, Mrózek, K, Volinia, S, Eisfeld, A-K, Radmacher, M D, Kohlschmidt, J, Metzeler, K H, Schwind, S, Whitman, S P, Mendler, J H, Wu, Y-Z, Nicolet, D, Paschka, P, Powell, B L, Carter, T H, Wetzler, M, Kolitz, J E, Carroll, A J, Baer, M R, Caligiuri, M A, Stone, R M, Marcucci, G, Bloomfield, C D

Get full text

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia by Whitman, S P, Caligiuri, M A, Maharry, K, Radmacher, M D, Kohlschmidt, J, Becker, H, Mrózek, K, Wu, Y-Z, Schwind, S, Metzeler, K H, Mendler, J H, Wen, J, Baer, M R, Powell, B L, Carter, T H, Kolitz, J E, Wetzler, M, Carroll, A J, Larson, R A, Marcucci, G, Bloomfield, C D

Get full text

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study by BECKER, Heiko, MAHARRY, Kati, CARTER, Thomas H, KOLITZ, Jonathan E, WETZLER, Meir, CARROLL, Andrew J, BAER, Maria R, MOORE, Joseph O, CALIGIURI, Michael A, LARSON, Richard A, MARCUCCI, Guido, BLOOMFIELD, Clara D, RADMACHER, Michael D, MROZEK, Krzysztof, METZELER, Klaus H, WHITMAN, Susan P, SCHWIND, Sebastian, KOHLSCHMIDT, Jessica, WU, Yue-Zhong, POWELL, Bayard L

“…The alleles of the Wilms tumor 1 (WT1) polymorphism rs16754 harbor adenine (A) or guanine (G). Recently, rs16754 has been reported to affect the outcome of…”
Get full text

Effects of a beverage containing an enzymatically induced-viscosity dietary fiber, with or without fructose, on the postprandial glycemic response to a high glycemic index food in humans by WOLF, B. W, WOLEVER, T. M. S, LAI, C. S, BOLOGNESI, C, RADMARD, R, MAHARRY, K. S, GARLEB, K. A, HERTZLER, S. R, FIRKINS, J. L

“…Dietary supplementation with guar gum or fructose has been reported to reduce the postprandial glycemic response to an oral glucose challenge. As a result of…”
Get full text

SO-21 Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study) by Velez, L., Trevino, T., Kopetz, S., Grothey, A., Yaeger, R., Gollerkeri, A., Maharry, K., Tabernero, J.

Get full text

G3139, a BCL-2 antisense oligo-nucleotide, in AML by Marcucci, G, Stock, W, Dai, G, Klisovic, M I, Maharry, K, Shen, T, Liu, S, Sher, D A, Lucas, D, Zwiebel, A, Larson, R A, Caligiuri, M A, Bloomfield, C D, Chan, K K, Grever, M R, Byrd, J C

Get full text

LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC by Grothey, A., Kopetz, S., Yaeger, R., Van Cutsem, E., Wasan, H., Desai, J., Ciardiello, F., Yoshino, T., Maharry, K., Christy-Bittel, J., Gollerkeri, A., Tabernero, J.

Get full text

Molecular variations in the calcium-sensing receptor in relation to sodium balance and presence of hypertension in blacks and whites by Pratt, J.Howard, Ambrosius, Walter T, Wagner, Mary Anne, Maharry, Kati

“…Sodium (Na) excretion is to an extent tied to calcium (Ca) excretion; increases in Ca result in increased Na excretion. We hypothesized that molecular…”
Get full text

85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study) by Chiu, C-F., Yeh, Y-M., Yeh, K-H., Desai, J., Price, T.J., Tebbutt, N., Tabernero, J., Velez, L., Trevino, T.L., Grothey, A., Yaeger, R., Gollerkeri, A., Maharry, K., Kopetz, S.

Get full text

LBA32 - Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) by Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y Sang, Steeghs, N., Guren, T.K., Arkenau, H.-T., García-Alfonso, P., Gollerkeri, A., Pickard, M., Maharry, K., Christy-Bittel, J.L., Anderson, L., Kopetz, S.

“…Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) significantly improved overall survival (OS, HR:0.52, P<0.0001) and objective response rates (ORR,…”
Get full text

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) by Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y Sang, Steeghs, N., Guren, T.K., Arkenau, H.-T., García-Alfonso, P., Gollerkeri, A., Pickard, M., Maharry, K., Christy-Bittel, J.L., Anderson, L., Kopetz, S.

Get full text

LBA32Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) by Tabernero, J, Grothey, A, Van Cutsem, E, Yaeger, R, Wasan, H, Yoshino, T, Desai, J, Ciardiello, F, Loupakis, F, Hong, Y Sang, Steeghs, N, Guren, T K, Arkenau, H-T, García-Alfonso, P, Gollerkeri, A, Pickard, M, Maharry, K, Christy-Bittel, J L, Anderson, L, Kopetz, S

“…Abstract Background Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) significantly improved overall survival (OS, HR:0.52, P < 0.0001) and objective…”
Get full text

O-027BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer by Van Cutsem, E, Cuyle, P, Huijberts, S, Schellens, J, Elez, E, Yaeger, R, Fakih, M, Montagut, C, Peeters, M, Desai, J, Yoshino, T, Ciardiello, F, Wasan, H, Maharry, K, Christy-Bittel, J, Gollerkeri, A, Kopetz, S, Grothey, A, Tabernero, J

Get full text